$ISCO
International Stem Cell CORP

2019 Q1 Form 10-Q Financial Statement

#000156459019019386 Filed on May 15, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $2.218M $2.633M
YoY Change -15.76% 31.0%
Cost Of Revenue $841.0K $825.0K
YoY Change 1.94% 50.0%
Gross Profit $1.377M $1.808M
YoY Change -23.84% 24.69%
Gross Profit Margin 62.08% 68.67%
Selling, General & Admin $2.178M $2.182M
YoY Change -0.18% 17.75%
% of Gross Profit 158.17% 120.69%
Research & Development $653.0K $811.0K
YoY Change -19.48% 25.74%
% of Gross Profit 47.42% 44.86%
Depreciation & Amortization $72.00K $68.00K
YoY Change 5.88% -17.07%
% of Gross Profit 5.23% 3.76%
Operating Expenses $653.0K $2.993M
YoY Change -78.18% 19.82%
Operating Profit -$1.489M -$1.185M
YoY Change 25.65% 13.07%
Interest Expense $14.00K $350.0K
YoY Change -96.0% 5733.33%
% of Operating Profit
Other Income/Expense, Net $583.0K $355.0K
YoY Change 64.23%
Pretax Income -$906.0K -$830.0K
YoY Change 9.16% -73.09%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$906.0K -$830.0K
YoY Change 9.16% -73.05%
Net Earnings / Revenue -40.85% -31.52%
Basic Earnings Per Share
Diluted Earnings Per Share -$122.4K -$135.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $620.0K $450.0K
YoY Change 37.78% -33.82%
Cash & Equivalents $615.0K $450.0K
Short-Term Investments
Other Short-Term Assets $480.0K $640.0K
YoY Change -25.0% 14.29%
Inventory $1.460M $1.390M
Prepaid Expenses
Receivables $960.0K $940.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.510M $3.410M
YoY Change 2.93% 4.28%
LONG-TERM ASSETS
Property, Plant & Equipment $1.590M $340.0K
YoY Change 367.65% -5.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $870.0K $790.0K
YoY Change 10.13% 12.86%
Total Long-Term Assets $5.150M $4.060M
YoY Change 26.85% -11.55%
TOTAL ASSETS
Total Short-Term Assets $3.510M $3.410M
Total Long-Term Assets $5.150M $4.060M
Total Assets $8.660M $7.470M
YoY Change 15.93% -4.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $810.0K $1.610M
YoY Change -49.69% 120.55%
Accrued Expenses $1.250M $860.0K
YoY Change 45.35% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.470M $5.830M
YoY Change -23.33% -19.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.010M
YoY Change
Total Long-Term Liabilities $1.010M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.470M $5.830M
Total Long-Term Liabilities $1.010M $0.00
Total Liabilities $5.477M $5.830M
YoY Change -6.05% -19.25%
SHAREHOLDERS EQUITY
Retained Earnings -$107.6M -$105.4M
YoY Change 2.09%
Common Stock $8.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.114M $1.639M
YoY Change
Total Liabilities & Shareholders Equity $8.663M $7.468M
YoY Change 16.0% -4.99%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$906.0K -$830.0K
YoY Change 9.16% -73.05%
Depreciation, Depletion And Amortization $72.00K $68.00K
YoY Change 5.88% -17.07%
Cash From Operating Activities -$341.0K -$48.00K
YoY Change 610.42% -91.58%
INVESTING ACTIVITIES
Capital Expenditures $58.00K $57.00K
YoY Change 1.75% 612.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$119.0K -$201.0K
YoY Change -40.8% 25.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -53.00K 392.0K
YoY Change -113.52% -69.85%
NET CHANGE
Cash From Operating Activities -341.0K -48.00K
Cash From Investing Activities -119.0K -201.0K
Cash From Financing Activities -53.00K 392.0K
Net Change In Cash -460.0K 143.0K
YoY Change -421.68% -74.91%
FREE CASH FLOW
Cash From Operating Activities -$341.0K -$48.00K
Capital Expenditures $58.00K $57.00K
Free Cash Flow -$399.0K -$105.0K
YoY Change 280.0% -81.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
933000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
294000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
182000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1011000
CY2019Q1 us-gaap Liabilities
Liabilities
5477000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
110742000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107569000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3186000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8663000
CY2019Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7533083
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7533083
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2633000
CY2019Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2018Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1489000
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-597000
CY2019Q1 us-gaap Interest Expense
InterestExpense
14000
CY2018Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000
CY2019Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1049000
CY2018Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
8000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
90000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
307000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-906000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-830000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
72000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
68000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
506000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
307000
CY2018Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
8000
CY2019Q1 isco Inventory Adjustment
InventoryAdjustment
3000
CY2018Q1 isco Inventory Adjustment
InventoryAdjustment
3000
CY2019Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
13000
CY2018Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1000
CY2019Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
18000
CY2019Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-4000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
348000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
292000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-288000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57000
CY2019Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
61000
CY2018Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
144000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-119000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-201000
CY2018Q1 isco Proceeds From Bridge Loan From Related Party
ProceedsFromBridgeLoanFromRelatedParty
350000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
90000
CY2019Q1 isco Payments On Financed Insurance Premiums
PaymentsOnFinancedInsurancePremiums
53000
CY2018Q1 isco Payments On Financed Insurance Premiums
PaymentsOnFinancedInsurancePremiums
48000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-53000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
392000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-460000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
143000
CY2017Q4 us-gaap Cash
Cash
304000
CY2018Q1 us-gaap Cash
Cash
447000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2019Q1 us-gaap Supplementary Insurance Information Premiums Written
SupplementaryInsuranceInformationPremiumsWritten
151000
CY2019Q1 isco Supplementary Information Lease Incentives Received For Leasehold Improvements And Construction In Progress
SupplementaryInformationLeaseIncentivesReceivedForLeaseholdImprovementsAndConstructionInProgress
162000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
506000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
307000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3450000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2019Q1 isco Revenue Generating Subsidiaries
RevenueGeneratingSubsidiaries
2
CY2006Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
133334
CY2019Q1 isco Burn Rate Excluding Capital Expenditures And Patent Costs
BurnRateExcludingCapitalExpendituresAndPatentCosts
96000
CY2019Q1 isco Percentage Of Ownership In Issue And Outstanding Share Of Common Stock Parent Company
PercentageOfOwnershipInIssueAndOutstandingShareOfCommonStockParentCompany
0.937
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3632000
CY2019Q1 isco Capital Expenditures And Patent Costs
CapitalExpendituresAndPatentCosts
40000
CY2019Q1 isco Maximum Original Maturities Period
MaximumOriginalMaturitiesPeriod
P3M
CY2019Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2019Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3692000
CY2008Q2 isco Number Of Accredited Investors
NumberOfAccreditedInvestors
5
CY2019Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2018Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
111000
CY2019Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
992000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
958000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
91000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2181000
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2617000
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2008Q2 isco Specified Amount Of Revenue To Be Utilized First For Advances
SpecifiedAmountOfRevenueToBeUtilizedFirstForAdvances
250000
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
30.00
CY2019Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2019Q1 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the anti-aging cosmetics products and biomedical products business segments. The cosmetic market segment markets and sells a line of luxury skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while the professional sales are to spas, salons and other skincare providers. The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, sold both within and outside the United States.
CY2019Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019Q1 isco Product Return Guarantee Period
ProductReturnGuaranteePeriod
P30D
CY2019Q1 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2018 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
2140156
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1054230
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3339031
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2040596
CY2019Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3951052
CY2018Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3951052
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
656000
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
590000
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1276000
CY2018Q4 us-gaap Inventory Gross
InventoryGross
2522000
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
216000
CY2018Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
2306000
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3317000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3121000
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2665000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2652000
CY2019Q1 isco Finite Lived Patents And Trademarks Gross
FiniteLivedPatentsAndTrademarksGross
2945000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
72000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
91000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
91000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
91000
CY2019Q1 isco Convertible Common Stock Conversion Price
ConvertibleCommonStockConversionPrice
1.75
CY2019Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19533571
CY2019Q1 isco Related Party Rent Expense
RelatedPartyRentExpense
40000
CY2018Q1 isco Related Party Rent Expense
RelatedPartyRentExpense
40000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
67500
CY2013Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
33750
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
30.00
CY2013Q1 isco Warrant Term
WarrantTerm
P5Y
CY2019Q1 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2018-01-31
CY2013Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
16667
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
33334
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3951052
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1305000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
119000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
933000
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y1M27D
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1738
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
372000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
369000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
347000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
220000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
227000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
454000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1989000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
684000
CY2019Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
140000
CY2018Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
87000
CY2018Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2018Q1 isco Number Of Business Units
NumberOfBusinessUnits
2
CY2018Q1 isco Number Of Products
NumberOfProducts
201

Files In Submission

Name View Source Status
0001564590-19-019386-index-headers.html Edgar Link pending
0001564590-19-019386-index.html Edgar Link pending
0001564590-19-019386.txt Edgar Link pending
0001564590-19-019386-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
isco-10q_20190331.htm Edgar Link pending
isco-20190331.xml Edgar Link completed
isco-20190331.xsd Edgar Link pending
isco-20190331_cal.xml Edgar Link unprocessable
isco-20190331_def.xml Edgar Link unprocessable
isco-20190331_lab.xml Edgar Link unprocessable
isco-20190331_pre.xml Edgar Link unprocessable
isco-ex311_9.htm Edgar Link pending
isco-ex312_7.htm Edgar Link pending
isco-ex321_6.htm Edgar Link pending
isco-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending